HCPLive

Related Tags

FDA Requests Removal of Generic Budeprion XL 300 mg

 
WEDNESDAY, Dec. 5 (HealthDay News) -- The U.S. Food and Drug Administration has concluded that generic Budeprion XL 300 mg (extended-release bupropion hydrochloride, manufactured by Impax Laboratories and distributed by Teva Pharmaceuticals) cannot be considered therapeutically equivalent to the brand-name product, according to a perspective piece published online Dec. 5 in the New England Journal of Medicine.

Noting that Budeprion XL 300 mg was approved based on extrapolation of the results of a bioequivalence study of Budeprion XL 150 mg and Wellbutrin XL 150 mg, Janet Woodcock, M.D., from the Center for Drug Evaluation and Research at the FDA in Rockville, Md., and colleagues reviewed new data providing direct comparative pharmacokinetic analyses of Budeprion XL 300 mg with Wellbutrin XL 300 mg. They conducted a bioequivalence study involving 24 healthy fasting volunteers in a single-dose crossover design.

The researchers found that the extent of bupropion absorption for the generic product was 86 percent of that of the brand-name product, and that the mean peak plasma concentration observed after Budeprion XL 300 mg administration was only 75 percent of that observed after administration of Wellbutrin XL 300 mg. In certain participants, the maximum plasma concentration and area under the plasma concentration curve for Budeprion XL were less than 40 percent of those for Wellbutrin. The time to peak drug concentration in the blood was shorter for Budeprion XL (four hours) than for Wellbutrin XL (five hours).

"We at the FDA are therefore changing our bioequivalence recommendations for extended-release bupropion products and have asked other manufacturers of 300-mg extended-release bupropion products to conduct additional bioequivalence studies," the authors write. "We do not believe that the results of the FDA study should cause concern regarding the overall reliability of the agency's approval process for generic drugs, including the use of extrapolation, when scientifically appropriate."
 

Full Text

 
Copyright © 2012 HealthDay. All rights reserved.
 
 

Most Popular

Recommended Reading

The results of the largest study of its kind to date indicate that new antipsychotic medications—including quetiapine, olanzapine, and risperidone—do not appear to put women at additional risk of developing gestational diabetes, hypertensive disorders, or major blood clots that obstruct circulation, all conditions that often develop during pregnancy or with the use of older antipsychotic medications.
Stiff and swollen joints may land some relief due to a newly discovered anti-inflammatory chemical compound.
Fatal drownings happen even in strong, healthy swimmers in lifeguarded pools. A New York City health department investigation points to an under-reported cause: deliberate breath-holding as part of informal contests or self-imposed training regimens.
In most cases when a patient undergoes a biopsy on their esophagus any cancer found is located too late to be treated. A recent development could help doctors find the disease before it is too late.
$vAR$